U.S. markets open in 58 minutes


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
13.29-0.69 (-4.94%)
At close: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close13.98
Bid13.00 x 4000
Ask0.00 x 800
Day's Range13.05 - 14.40
52 Week Range13.05 - 19.80
Avg. Volume59,030
Market Cap848.668M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.23
Earnings DateSep 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for SOPH

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    A: Lowering target price to $168.00AGILENT TECHNOLOGIES INC has an Investment Rating of BUY; a target price of $168.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium.
    Fair Value
    Economic Moat
    8 days agoArgus Research
View more
  • PR Newswire

    SOPHiA GENETICS Announces Launch of DEEP-Lung-IV Multimodal Clinical Study

    SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced today the launch of their DEEP-Lung-IV clinical study (NCT04994795). The study leverages deep learning-enabled analysis of the aggregation of multimodal clinical, biological, genomic and radiomics data to identify and validate predictive signatures associated with response to immunotherapy and prognosis of patients with metastatic non-small cell lun

  • PR Newswire

    SOPHiA GENETICS Hosts Symposium with GE Healthcare at RSNA 2021

    SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced today they will be hosting a joint symposium with GE Healthcare titled "Advancing data-driven medicine: unlocking the potential of multimodal digital health data sets by combining longitudinal radiomics and genomics data with AI-powered analytics," during the Radiological Society of North America 2021 Annual Meeting at 9:30am CT on Wednesday, Decemb

  • Motley Fool

    Sophia Genetics SA (SOPH) Q3 2021 Earnings Call Transcript

    Earlier today SOPHiA GENETICS released financial results for the quarter ended September 30, 2021. Joining me today from SOPHiA GENETICS Sofia are Jurgi Camblong, co-founder and CEO; Ross Muken, chief financial officer; Lara Hashimoto, chief business officer; and Philippe Menu, chief medical officer.